RTP Mobile Logo
Oncology Grand Rounds Series: Non-Small Cell Lung Cancer (Webinar Audio Proceedings) — an NCPD-Accredited Program for Nurses
Released May 2021

Proceedings from the second in a series of 11 integrated webinars held in association with the 2021 ONS Annual Congress. Featuring perspectives from Drs John V Heymach, Paul K Paik and Zofia Piotrowska on cases from the practices of Ms Kelly EH Goodwin, Ms Tara Plues and Ms Victoria Sherry. (Audio Program)

CE Disclosures and Faculty Information

    This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of lung cancer.

    By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with non-small cell lung cancer.


    • Acknowledge available Phase III findings supporting the use of adjuvant osimertinib for patients with early-stage non-small cell lung cancer (NSCLC) with EGFR mutations, and consider the potential effects of this information on current and future clinical practice.
    • Review published research data documenting the safety and efficacy of EGFR tyrosine kinase inhibitors alone or in combination with other systemic approaches for metastatic NSCLC with an EGFR tumor mutation, and discern how this information should be applied outside of a research setting.
    • Assess the efficacy and safety of commercially available ALK inhibitors for patients with metastatic NSCLC and an ALK rearrangement, and apply this understanding to the selection and sequencing of these drugs as first- and later-line therapy.
    • Review recent therapeutic advances related to the use of anti-PD-1/PD-L1 antibodies as monotherapy or in combination with chemotherapy or chemobiologic therapy for metastatic NSCLC, and discern how these approaches can be optimally employed in the management of this disease.
    • Recognize common side effects associated with novel systemic agents in the treatment of NSCLC, and implement supportive management strategies to minimize and ameliorate these toxicities.

    Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

    NCPD credit is no longer available for this issue

    The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit ResearchToPractice.com/ONSNSCLC2021/ILNA.

    ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

    Audio Program: This NCPD activity consists of an audio component.
    NCPD credit is no longer available for this issue

    Video Program: This NCPD activity consists of a video component.
    NCPD credit is no longer available for this issue

    RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of NCPD activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant conflicts of interest, which have been mitigated through a conflict of interest mitigation process:

    John V Heymach, MD, PhD
    Professor and Chair
    Thoracic/Head and Neck Medical Oncology
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Advisory Committee and Consulting Agreements: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, BrightPath Biotherapeutics Co Ltd, Bristol-Myers Squibb Company, Catalyst Pharmaceuticals, EMD Serono Inc, Foundation Medicine, Genentech, a member of the Roche Group, GlaxoSmithKline, Guardant Health, Hengrui Therapeutics Inc, Janssen Biotech Inc, Kairos Venture Investments LLC, Leads Biolabs, Lilly, Mirati Therapeutics, Nexus Health Systems, Novartis, Pneuma Respiratory, Roche Laboratories Inc, Sanofi Genzyme, Spectrum Pharmaceuticals Inc, Takeda Oncology; Contracted Research: AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Spectrum Pharmaceuticals Inc; Licensing and Fees: Spectrum Pharmaceuticals Inc.

    Paul K Paik, MD
    Associate Attending Physician
    Clinical Director, Thoracic Oncology Service
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Advisory Committee: Calithera Biosciences, EMD Serono Inc, Xencor; Consulting Agreements: Bicara Therapeutics, a wholly owned subsidiary of Biocon, Boehringer Ingelheim Pharmaceuticals Inc, GlaxoSmithKline; Contracted Research: EMD Serono Inc; Data and Safety Monitoring Board/Committee: Takeda Oncology.

    Zofia Piotrowska, MD, MHS
    Assistant Professor of Medicine
    Harvard Medical School
    Massachusetts General Hospital
    Boston, Massachusetts

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Blueprint Medicines, C4 Therapeutics, Genentech, a member of the Roche Group, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medtronic Inc, Takeda Oncology; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Cullinan Oncology, Daiichi Sankyo Inc, Janssen Biotech Inc, Novartis, Spectrum Pharmaceuticals Inc, Takeda Oncology, Tesaro, A GSK Company.

    Oncology Nurse Practitioners

    Kelly EH Goodwin, MSN, RN, ANP-BC
    Thoracic Cancer Center
    Massachusetts General Hospital
    Boston, Massachusetts

    No relevant conflicts of interest to disclose.

    Tara Plues, APRN, MSN
    Hematology and Medical Oncology
    Cleveland Clinic
    Cleveland, Ohio

    No relevant conflicts of interest to disclose.

    Victoria Sherry, DNP, CRNP, AOCNP
    Oncology Nurse Practitioner for Thoracic Malignancies
    Abramson Cancer Center
    Perelman Center for Advanced Medicine
    University of Pennsylvania Medical Center
    Faculty, University of Pennsylvania School of Nursing
    Philadelphia, Pennsylvania

    Advisory Committee and Consulting Agreement: AstraZeneca Pharmaceuticals LP.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME/NCPD activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Turning Point Therapeutics Inc and Verastem Inc.

    RTP NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Merck, Regeneron Pharmaceuticals Inc and Sanofi Genzyme, and Takeda Oncology.

    Release date: May 2021
    Expiration date: May 2022

    There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):